| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WFDC12 |
| Uniprot No | Q8WWY7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-111aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSVKEGIEKAGVCPADNVRCFKSDPPQCH TDQDCLGERKCCYLHCGFKCVIPVKELEEGGNKDEDVSRPYPEPGWEAKC PGSSSTRCPQK |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WFDC12重组蛋白的3篇参考文献概览：
---
1. **标题**: *Recombinant Expression and Functional Characterization of WFDC12 in Airway Epithelial Defense*
**作者**: Smith A, et al.
**摘要**: 本研究成功在大肠杆菌中表达了重组WFDC12蛋白，并验证其在体外对铜绿假单胞菌的抑菌活性。结果表明WFDC12通过破坏细菌膜完整性发挥抗菌作用，提示其在呼吸道免疫防御中的潜在应用。
2. **标题**: *WFDC12 as a Novel Biomarker in Ovarian Cancer: Production and Clinical Validation*
**作者**: Zhang L, et al.
**摘要**: 通过哺乳动物细胞系统(CHO)重组表达WFDC12蛋白，用于开发卵巢癌诊断试剂。研究发现血清WFDC12水平与肿瘤进展呈正相关，重组蛋白在免疫检测中表现出高灵敏度和特异性。
3. **标题**: *Structural Analysis of WFDC12 Reveals Its Role in Protease Inhibition*
**作者**: Tanaka K, et al.
**摘要**: 利用昆虫细胞系统表达WFDC12重组蛋白，并通过晶体学解析其三维结构。研究发现WFDC12通过特定的结构域抑制弹性蛋白酶活性，为设计基于其结构的抗炎药物提供了依据。
---
注：以上文献为示例，实际研究中建议通过学术数据库(如PubMed、Web of Science)以最新关键词检索。若WFDC12相关研究有限，可扩展至WFDC家族蛋白或功能类似物的重组表达文献。
WFDC12 (WAP Four-Disulfide Core Domain Protein 12) is a member of the WFDC family, characterized by conserved structural motifs involved in protease inhibition and immune regulation. This secretory protein, encoded by the WFDC12 gene in humans, contains a canonical WAP-type four-disulfide core (WFDC) domain, a signature feature comprising eight conserved cysteine residues forming four disulfide bonds that stabilize its tertiary structure. Initially identified through genomic sequencing, WFDC12 has drawn attention for its tissue-specific expression patterns and potential roles in pathophysiological processes.
Functionally, WFDC12 is hypothesized to act as a protease inhibitor, modulating extracellular proteolytic activities linked to inflammation, tissue remodeling, and cancer progression. Emerging studies suggest its involvement in regulating cellular proliferation, apoptosis, and immune responses, though precise mechanisms remain under investigation. WFDC12 expression is notably elevated in certain cancers, including ovarian, prostate, and lung carcinomas, where it may contribute to tumor microenvironment modulation or therapeutic resistance. Its interaction with extracellular matrix components and signaling pathways, such as Wnt/β-catenin or EGFR, has been proposed but requires further validation.
Recombinant WFDC12 protein is typically produced using heterologous expression systems (e.g., E. coli, mammalian cells) for functional studies. Purification often employs affinity tags to isolate the bioactive form, enabling in vitro assays to explore its biochemical properties and ligand interactions. Current research focuses on deciphering its diagnostic or therapeutic potential, particularly as a biomarker for cancer or inflammatory diseases. However, knowledge gaps persist regarding its physiological ligands, regulatory networks, and tissue-specific functions, necessitating deeper mechanistic exploration to unlock its clinical relevance.
×
